1stOncology™: Cancer Intelligence Service – Page 14323 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Veracyte to Release Fourth Quarter and Full-Year 2018 Financial Results February 25, 2019

On January 28, 2019 Veracyte, Inc. (Nasdaq: VCYT) reported that it will release its financial results for the fourth quarter and full-year 2018 after the close of market on Monday, February 25, 2019 (Press release, Veracyte, JAN 28, 2019, View Source [SID1234532926]). Company management will host a conference call and webcast to discuss its financial results and provide a general business update at 5:00 p.m. Eastern time on the same day.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The conference call will be webcast live from the company’s website and will be available via the following link: View Source The webcast should be accessed 10 minutes prior to the conference call start time. A replay of the webcast will be available for one year following the conclusion of the live broadcast and will be accessible on the company’s website at View Source

The conference call can be accessed as follows:

U.S./Canada participant dial-in number (toll-free): (855) 541-0980
International participant dial-in number: (970) 315-0440
Conference I.D.: 5498321

UroGen Pharma Announces Closing of Public Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares

On January 28, 2019 UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, reported the closing of its previously announced public offering of 4,207,317 ordinary shares, including 548,780 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares (Press release, UroGen Pharma, JAN 28, 2019, View Source [SID1234532925]). All of the ordinary shares were sold at a price to the public of $41.00 per share. The net proceeds of the public offering are approximately $162.1 million, after deducting the underwriting discounts and commissions but before payment of other offering expenses. All ordinary shares sold in the offering were offered by the Company.

Goldman Sachs & Co. LLC, J.P. Morgan and Jefferies acted as joint book-running managers for the offering. Oppenheimer & Co. acted as lead manager for the offering.

A shelf registration statement relating to the ordinary shares was previously filed with the Securities and Exchange Commission (the "SEC") and declared effective on October 26, 2018. A final prospectus supplement and accompanying prospectus relating to the offering was filed with the SEC and is available on the SEC’s website at View Source Copies of the final prospectus supplement and accompanying prospectus may be obtained by contacting:

Goldman Sachs & Co. LLC, c/o: Prospectus Department, 200 West Street, New York, New York 10282, or via telephone at 866-471-2526, or via email: [email protected]; or
J.P. Morgan Securities LLC, c/o: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or via telephone at 866-803-9204, or via email: [email protected]; or
Jefferies LLC, c/o: Equity Syndicate Prospectus Departments, 520 Madison Avenue, 2nd Floor, New York, New York 10022, or via telephone at 877-821-7388, or via email: [email protected].
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

Physicians’ Education Resource® Presents the 23rd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma

On January 28, 2019 Physicians’ Education Resource (PER), a leading resource for continuing medical education (CME), reported that it will host its 23rd annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma from Thursday, Feb. 28 to Sunday, March 3 at the Eden Roc Miami Beach in Florida (Press release, Physicians’ Education Resource, JAN 28, 2019, View Source [SID1234532924]).

This dynamic Winter Hematology congress will be co-chaired by Andre Goy, M.D., M.S., the chairman and executive director of the lymphoma division and chief of the John Theurer Cancer Center at Hackensack University Medical Center, chief science officer and director of research and innovation of the Regional Cancer Care Associates; Sagar Lonial M.D., FACP, a professor and executive vice chair in the department of hematology and medical oncology at Emory School of Medicine, and chief medical officer of Winship Cancer Institute of Emory University; and Jorge Eduardo Cortes, M.D., the D.B. Lane Cancer Research Distinguished Professor for Leukemia Research, deputy chair and professor of medicine, and an internist in the department of leukemia, division of cancer medicine at The University of Texas MD Anderson Cancer Center.

"Our winter hematology congress continually offers the latest updates and insights in the evolving field of hematologic oncology," said Phil Talamo, president of PER. "With all the recent advancements this past year, this conference will discuss new data and challenge participants to apply new information they have learned, reflect on new practices they can bring back to their clinics to share with their peers, and ultimately improve patient outcomes."

The 23rd annual congress is a three-and-a-half-day engaging and highly interactive meeting that provides community-based hematologists and medical oncologists interested in the treatment of hematologic malignancies with the opportunity to interact with internationally renowned experts in the management of leukemias, lymphomas, myeloma, myelodysplastic syndromes, myeloproliferative neoplasms, and benign hematologic malignancies. During the congress, faculty experts will review latest information on pressing topics for 2019, including the expanding role of new immunologic approaches, including CAR T cells and checkpoint inhibitors, the emergence of molecular-based therapies and new cytotoxic formulations in patients with acute leukemias, new approaches for treatment and duration of therapy among patients with myeloproliferative neoplasms and more. The meeting will also feature several engaging Medical Crossfire discussion panels interspersed throughout the meeting to allow attendees to explore some of the most challenging clinical situations in the management of hematologic malignancies.

Oragenics, Inc. Receives Further Validation for Lantibiotic Compound OG716

On January 28, 2019 Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis ("OM"), reported the publication of a preclinical study using the lead compound from its lantibiotics program, OG716, in the peer reviewed journal, Antimicrobial Agents and Chemotherapy (Press release, Oragenics, JAN 28, 2019, View Source [SID1234532923]).

The preclinical study demonstrated that following oral administration of the maximum feasible dose of OG716 in hamster models, there were no observable toxicities nor observable side effects, nor was there any effect on intestinal motility. Treatment of animals infected with C. difficile resulted in a dose-dependant survival, and no recurrence at the upper dose tested. Further, researchers observed that the compound remained constrained only in the gastrointestinal tract. Lantibiotics, including OG716, are a novel class of peptide antibacterial compounds naturally produced by a variety of Gram-positive bacteria. Oragenics’ lantibiotic library offers a large pipeline for the development of novel antibiotics in several indications.

"The publication of this study offers additional validation for the safety and tolerability of our lantibiotic program, while simultaneously confirming the potential for our lead candidate for the treatment of CDAD," stated Alan Joslyn, Ph.D., President and CEO of Oragenics, Inc. "There exists a dire need for new approaches to fighting antibiotic-resistant infections, and we believe the continued development of our lantibiotic program is one of those potential solutions. We look forward to providing continued updates on the development of OG716 as they become available."

The manuscript is available on-line at View Source

About Lantibiotics and OG716

OG716 is a molecule derived from Oragenics’ lantibiotic discovery and characterization platform that has shown positive results in nonclinical testing including efficacy in an animal model for Clostridium difficile infection in enteritis. Lantibiotics are a class of antibiotic compounds with novel mechanism of action, prized for their ability to overcome antibiotic-resistant infections. With resistant strains on the rise, particularly healthcare-acquired infections (HAI), the need for these potent lantibiotic agents is critical. Oragenics is pursuing the commercial-scale production of a lantibiotic for use as an antimicrobial.

Advaxis To Present An Overview Of Its Lm Platform And New Information On Its Neoantigen-Directed Therapy Programs At The Immuno-Oncology 360° Conference

On January 28, 2019 Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, reported that an overview of the Company’s proprietary Lm platform and new information regarding the Company’s neoantigen-directed therapy programs, ADXS-NEO (customized, personalized neoantigens) and ADXS-HOT (off-the-shelf, hotspot or shared neoantigens and other antigens), will be presented during a plenary session at the Immuno-Oncology 360° conference on February 6, 2019 (Press release, Advaxis, JAN 28, 2019, View Source [SID1234532920]). The conference is being held at the Crowne Plaza Times Square in New York City; the plenary session begins at 4:00 p.m. ET and the Advaxis presentation is scheduled to begin at 4:40 p.m. ET.

The presentation will be made by Andres A. Gutierrez, M.D., Ph.D., Chief Medical Officer and Executive Vice President of Advaxis, and Robert G. Petit, Ph.D., Chief Scientific Officer and Executive Vice President of Advaxis. Advaxis intends to issue a news release on February 6, 2019, that summarizes the presentation by Drs. Gutierrez and Petit.

ADXS-NEO, the Company’s personalized neoantigen program, is in an ongoing Phase 1 dose-escalation study to treat a variety of cancers. ADXS-HOT is the Company’s off-the-shelf program and consists of several different drug constructs which target hotspot or shared neoantigens, and other antigens. The first drug construct from this program is ADXS-503, or HOT-Lung, for the treatment of non-small cell lung cancer. ADXS-503 is expected to enter the clinic this quarter.